Crenolanib besylate is under clinical development by Arog Pharmaceuticals and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Crenolanib besylate’s likelihood of approval (LoA) and phase transition for Gliosarcoma took place on 22 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 22 Oct 2020 increased Crenolanib besylate’s Phase Transition Success Rate (PTSR) for Recurrent Glioblastoma Multiforme (GBM).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Crenolanib besylate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Crenolanib besylate overview

Crenolanib besylate (CP-868-596) is under development for the treatment of relapsed/refractory acute myeloid leukemia, gastrointestinal stromal tumor (GIST), acute myelocytic leukemia, gliosarcoma, recurrent/refractory glioblastoma multiforme (GBM), and soft tissue sarcoma and systemic mastocytosis. The drug candidate is administered orally as tablet. It acts by targeting platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta and FMS-related tyrosine kinase 3 (FLT3). The drug candidate was also under development for the treatment of adenocarcinoma of the gastroesophageal junction, stomach (gastric) and esophagus, malignant glioma, soft tissue sarcoma in US, low-grade glioma, non-small cell lung cancer and pediatric diffuse intrinsic pontine glioma, high grade glioma.

Arog Pharmaceuticals overview

Arog Pharmaceuticals is a biopharmaceutical company which discovers and develops small molecules for the treatment of cancers. The company’s lead product candidate Crenolanib, a mutation resistant pan-FLT3 inhibitor is designed to treat acute myeloid leukemia, glioma and gastric cancer. It also develops drugs for treating gastrointestinal stromal tumor, chronic myelomonocytic leukemia, lung cancer, solid tumors and other cancers. The company works in collaboration with investigators and institutions across the US. Arog Pharmaceuticals is headquartered in Dallas, Texas, the US.

Quick View Crenolanib besylate LOA Data

Report Segments
  • Innovator
Drug Name
  • Crenolanib besylate
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.